These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 32394008)
1. Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination. Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S Apoptosis; 2020 Jun; 25(5-6):370-387. PubMed ID: 32394008 [TBL] [Abstract][Full Text] [Related]
2. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma. Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933 [TBL] [Abstract][Full Text] [Related]
3. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173 [TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916 [TBL] [Abstract][Full Text] [Related]
5. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. Lee DH; Kim GW; Kwon SH Mol Carcinog; 2019 Jun; 58(6):944-956. PubMed ID: 30693983 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib. Amengual JE; Prabhu SA; Lombardo M; Zullo K; Johannet PM; Gonzalez Y; Scotto L; Serrano XJ; Wei Y; Duong J; Nandakumar R; Cremers S; Verma A; Elemento O; O'Connor OA Clin Cancer Res; 2017 Jun; 23(12):3084-3096. PubMed ID: 27993968 [No Abstract] [Full Text] [Related]
7. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444 [No Abstract] [Full Text] [Related]
8. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma. Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760 [TBL] [Abstract][Full Text] [Related]
9. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308 [TBL] [Abstract][Full Text] [Related]
11. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells. Yeh CT; Huang WC; Rao YK; Ye M; Lee WH; Wang LS; Tzeng DT; Wu CH; Shieh YS; Huang CY; Chen YJ; Hsiao M; Wu AT; Yang Z; Tzeng YM Carcinogenesis; 2013 Dec; 34(12):2918-28. PubMed ID: 23880305 [TBL] [Abstract][Full Text] [Related]
12. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080 [TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells. Dos Santos Ferreira AC; Fernandes RA; Kwee JK; Klumb CE J Cancer Res Clin Oncol; 2012 Feb; 138(2):317-25. PubMed ID: 22131152 [TBL] [Abstract][Full Text] [Related]
14. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition. Liu T; Li A; Xu Y; Xin Y Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175 [TBL] [Abstract][Full Text] [Related]
15. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway. Zhang H; Chi F; Qin K; Mu X; Wang L; Yang B; Wang Y; Bai M; Li Z; Su L; Yu B Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847 [TBL] [Abstract][Full Text] [Related]
16. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Buglio D; Mamidipudi V; Khaskhely NM; Brady H; Heise C; Besterman J; Martell RE; MacBeth K; Younes A Br J Haematol; 2010 Nov; 151(4):387-96. PubMed ID: 20880107 [TBL] [Abstract][Full Text] [Related]
17. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines. Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715 [TBL] [Abstract][Full Text] [Related]
18. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870 [TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Doi S; Soda H; Oka M; Tsurutani J; Kitazaki T; Nakamura Y; Fukuda M; Yamada Y; Kamihira S; Kohno S Mol Cancer Ther; 2004 Nov; 3(11):1397-402. PubMed ID: 15542778 [TBL] [Abstract][Full Text] [Related]
20. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]